HRASLS2

HRASLS2 (also known as PLAAT2) belongs to the H-RAS-like suppressor/phospholipase A and acyltransferase (HRASLS/PLAAT) family, a group of lipid-metabolizing enzymes originally identified through their association with class II tumor suppressor activity and negative regulation of Ras-related signaling pathways^[1][2]. Mechanistically, HRASLS2 functions as a Ca²⁺-independent phospholipid-metabolizing enzyme that exhibits phospholipase A₁/A₂ and acyltransferase activities, thereby participating directly in phospholipid remodeling and membrane lipid homeostasis^[1][3]. Through these enzymatic activities, HRASLS2 contributes to the generation and turnover of bioactive lipid intermediates that are linked to cellular growth control and signaling regulation^[1][2]. In disease-related studies, HRASLS family proteins were initially characterized as tumor suppressor-associated factors, and HRASLS2 has been reported to suppress colony formation and promote cell death in several cancer cell models, supporting its relevance to cancer biology and experimental oncology research^[2]. Compared with related isoforms, HRASLS2 shares the conserved catalytic framework of the HRASLS/PLAAT family but displays distinct enzymatic properties and physiological functions, indicating that individual family members participate in phospholipid metabolism through non-identical mechanisms and biological contexts^[1][3]. Therefore, HRASLS2 serves as a useful experimental model for investigating lipid metabolic regulation, phospholipid remodeling, and the relationship between membrane lipid homeostasis and tumor-associated cellular phenotypes^[1][2][3].